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Background: Although opioid-agonist therapy with methadone or buprenorphine/naloxone is currently the mainstay
of medical treatment for opioid use disorder, these medications often are not well accepted or tolerated by patients.
Recently, extended release naltrexone (XR-NTX), an opioid antagonist, has been advanced as an alternative treatment.
The willingness of opioid-addicted patients to take XR-NTX has not been well described.
Methods: Opioid-using persons enrolled in a community-recruited cohort in Vancouver, Canada, were asked whether or
not they would be willing to take XR-NTX. Logistic regression was used to independently identify factors associated with
willingness to take the medication.
Results: Among the 657 participants surveyed between June 1, 2013, and November 30, 2013, 342 (52.1%) were willing
to take XR-NTX. One factor positively associated with willingness was daily heroin injection (adjusted odds ratio [AOR] =
1.53; 95% confidence interval [CI] = 1.02–2.31), whereas Caucasian ethnicity was negatively associated (AOR = 0.59; 95%
CI = 0.43–0.82). Satisfaction with agonist therapy (13.4%) and unwillingness to stop opioids being used for pain (26.9%)
were the most common reasons for being unwilling to take XR-NTX.
Conclusions: A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection
heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take
XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to
investigate real-world acceptability of XR-NTX as an additional option for the treatment of opioid use disorder.
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Opioid use disorder remains a major public health con-
cern worldwide. Globally, opioids top the list of illicit
drugs that cause substantial morbidity and mortality [1].
In the United States alone, over 5 million people abused
prescription pain relievers in 2010 [2]. Nonmedical users
of prescription opioids have also been shown to be al-
most 8 times more likely to use heroin and over 4 times
more likely to use intravenously [3].* Correspondence: uhri-ew@cfenet.ubc.ca
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unless otherwise stated.While the health and social consequences of opioid
use disorder are well documented, past studies have
clearly demonstrated significant reductions in these con-
sequences through medically assisted treatment with
methadone or buprenorphine, which are the gold stan-
dards for medical management of opioid use disorder
[4-7]. In terms of psychosocial treatments, past studies
have generally shown that without opioid-agonist medi-
cations like methadone or buprenorphine, the vast
majority of patients will be treatment-refractory to psy-
chosocial and nonpharmacological interventions [4,8].
Unfortunately, due to the real or perceived side effects
or programmatic characteristics, treatment with metha-
done and buprenorphine does not attract all users into
treatment. Commonly reported barriers to programl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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threshold of treatment programs (i.e., safe dose titration
timelines), and requirements that opioid-agonist medica-
tions must be provided via daily, witnessed ingestion [9].
Furthermore, while they vary from setting to setting,
retention rates with opioid-agonist treatments are only
approximately 60 percent, and many patients on metha-
done or buprenorphine should remain on this medication
indefinitely [10-12]. Oral naltrexone, an opioid-receptor
antagonist, has been proposed as an alternative for pa-
tients. Naltrexone has several advantages in that it has few
drug–drug interactions, no physical dependence, and a fa-
vorable side-effect profile [13]. Unfortunately, due to the
requirement for daily oral dosing, medication adherence
has been the major barrier to its efficacy [14].
Recently, naltrexone for extended-release injectable
suspension (XR-NTX), which is administered via intra-
muscular injection every 4 weeks, has been advanced as
an alternative treatment [15,16]. Placebo-controlled trials
have demonstrated its efficacy in retaining patients in
treatment, increasing abstinence, and decreasing opioid
cravings [15-17]. However, it has recently been noted
that the willingness of opioid-addicted patients to take
XR-NTX has not been well described [18]. Since little is
known about the willingness of opioid-addicted patients
to take an extended-release, opioid-antagonist medica-
tion (or about factors that may predict willingness), we
undertook this study to examine the willingness to use
XR-NTX among opioid-addicted patients participating
in a cohort study in Vancouver, Canada.
Methods
Data for this study were derived from the Vancouver Injec-
tion Drug Users Study (VIDUS), an open, prospective co-
hort of HIV-seronegative individuals who inject drugs, and
the AIDS Care Cohort to Evaluate Access to Survival Ser-
vices (ACCESS), an open, prospective cohort of HIV-
seropositive individuals who use illicit drugs in Vancouver,
Canada. Detailed methodology has previously been de-
scribed [19,20]. Participants were eligible for the study if
they were 18 years or older, used illicit drugs other than
cannabis within the past month, resided in the Greater
Vancouver region, and provided informed consent. Partici-
pants were recruited through extensive street-based out-
reach methods and snowball sampling, beginning in May
1996. At baseline and every 6 months thereafter, partici-
pants completed an interviewer-administered question-
naire that elicited information regarding sociodemographic
characteristics, drug use, HIV risk behaviors, and treatment
utilization, and underwent an examination by a nurse. Par-
ticipants received a $20 CAD stipend for each visit. VIDUS
and ACCESS study recruitment and follow-up procedures
were essentially identical, with the exception of questions
specific to HIV infection, to enable merged analyses. Boththe VIDUS and ACCESS studies were ethically approved
by the Research Ethics Board of Providence Health Care/
University of British Columbia.
For the primary analysis, we restricted the study sam-
ple to those who reported any use of opioids or who en-
rolled in methadone maintenance therapy in the past
6 months, and assessed whether participants were will-
ing to take XR-NTX for opioid addiction treatment by
adding questions to follow-up visits between June 1,
2013, and November 30, 2013. Specifically, participants
were asked: “There is a new medication that can be
given to people who have detoxed from heroin or other
opioids, including methadone. It is given by intramuscu-
lar injection. It completely blocks the effects of opioids,
including pain medications, for 30 days. If you are on
methadone or using other opioid drugs, would you be
interested in taking this medication if it becomes avail-
able in Canada?” Since XR-NTX was not available in
Canada at the time these questions were utilized, staff
were trained to answer questions about the medication’s
effects, induction, and duration of action. Participants
who answered “Yes” were compared to those who an-
swered “No” on a variety of a priori-selected sociodemo-
graphic, behavioral, and drug use variables hypothesized
to be associated with willingness to take XR-NTX.
These variables included: age (per year older); female
gender (yes vs. no); ethnicity (Caucasian vs. other); daily
heroin injection (yes vs. no); daily cocaine injection (yes
vs. no); daily crack smoking (yes vs. no); homelessness
(yes vs. no); involvement in sex work, defined as exchan-
ging sex for money, gifts, food, shelter, clothes, drugs, or
other commodities (yes vs. no); HIV seropositivity (yes
vs. no); or participation in drug treatment, defined as al-
cohol and/or drug treatment other than methadone
treatment (yes vs. no). All behavioral and drug use char-
acteristics refer to the 6-month period prior to the inter-
view. All variable definitions have been used extensively
and were identical to earlier publications [21,22].
We used bivariate and multivariate logistic regression
analyses to determine factors associated with the willing-
ness to take XR-NTX. To identify the independent cor-
relates of willingness to take XR-NTX, only variables
that were associated with willingness at p-value < 0.10 in
bivariate analyses were considered in the full multivari-
ate model. Using the backwards-selection procedure, we
constructed the final multivariate model with the best
fit, as indicated by the lowest Akaike Information Criter-
ion (AIC) value.
As a sub-analysis among participants who did not report
any willingness to take XR-NTX, their reasons from the
subsequent question were collated. Participants could se-
lect more than one response from the following reasons:
“Not using opioids”; “happy with methadone/suboxone
(buprenorphine/naloxone)”; “don’t feel that I could detox
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could not get off my pain med”; “don’t want to take a
long-acting medication by injection”; and “other”. All stat-
istical analyses were performed using SAS software ver-
sion 9.3 (SAS, Cary, NC, USA). All statistical tests were
two-sided, with alpha = 0.05.
Results
Between June 1, 2013, and November 30, 2013, 657
opioid-using VIDUS and ACCESS participants were
interviewed and included in the present analysis. Among
these individuals, median age was 48 (inter-quartileTable 1 Characteristics of study participants assessed for will
Characteristic Willingness
No = 315 (%)

























Participation in drug treatment**
No 257 (81.6)
Yes 57 (18.1)
NOTE: Percentages do not necessarily sum to 100% due to missing data or roundin
*Activities in last 6 months.
**Defined as drug and/or alcohol treatment other than a methadone program.
¥IQR = inter-quartile range.
£CI = confidence interval.range = 41–53); 249 (37.9%) were female; and 397
(60.4%) were Caucasian (Table 1).
Of the 657 participants, 342 (52.1%) indicated a will-
ingness to take XR-NTX. As shown in Table 1, the
sociodemographic, behavioral, and drug use character-
istics associated with a willingness to take XR-NTX in
unadjusted analyses included: age, female gender, daily
heroin injection, and Caucasian ethnicity (all p < 0.05).
The results of the multivariate analysis are presented in
Table 2. Factors independently associated with a will-
ingness to take XR-NTX included: daily heroin injec-




Yes = 342 (%)
46 (40–51) 0.98 (0.96–1.00) 0.015
199 (58.2)
143 (41.8) 1.42 (1.03–1.95) 0.032
158 (46.2)
184 (53.8) 0.56 (0.41–0.77) < 0.001
270 (79.0)
71 (20.8) 1.50 (1.00–2.25) 0.050
319 (93.3)
23 (6.7) 0.80 (0.45–1.44) 0.457
279 (81.6)
63 (18.4) 0.89 (0.60–1.30) 0.538
295 (86.3)
46 (13.5) 1.01 (0.65–1.59) 0.953
312 (91.2)
30 (8.8) 1.28 (0.72–2.27) 0.397
198 (57.9)
144 (42.1) 1.09 (0.80–1.49) 0.584
275 (80.4)
64 (18.7) 1.05 (0.71–1.56) 0.812
g error.
Table 2 Multivariate analysis of factors associated with
the willingness to take an opioid antagonist (N = 657)
Characteristic Adjusted odds ratio 95% CI£ p value
Daily heroin injection*
Yes vs. No 1.53 1.02–2.31 0.043
Female gender
Yes vs. No 1.29 0.93–1.79 0.133
Caucasian ethnicity
Yes vs. No 0.59 0.43–0.82 0.002
£CI = confidence interval.
*Activities in last 6 months.
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(AOR = 0.59; 95% CI = 0.43–0.82]).
As shown in Figure 1, of the 315 (47.9%) participants
who indicated that they would not be willing to take
XR-NTX, 320 reasons were given for unwillingness and
included: 53 (16.6%) reported that they were not actively
taking opioids; 43 (13.4%) were happy with methadone/
suboxone (buprenorphine/naloxone); 25 (7.8%) didn’t
feel that they could detox from opioids; 86 (26.9%) didn’t
feel that they could get off pain medications; 7 (2.2%)
didn’t want to take a long-acting medication by injec-
tion; 9 (2.8%) reported concern regarding untreated pain
if injured; 23 (7.2%) reported they liked using heroin; 11
(3.4%) reported needing more information; and 63Figure 1 Reasons given by participants who indicated they would not be(19.7%) reported a variety of other reasons that were not
consistent enough to be collapsed into categories. Data
are available from the corresponding author.
Discussion
In the present study, we found high rates of willingness
to take XR-NTX among a community-recruited cohort
of opioid drug users. We also found that daily heroin
use was independently associated with a higher likeli-
hood of willingness to take XR-NTX, whereas Caucasian
participants were associated with a lower likelihood of
willingness. Among the reasons reported for unwilling-
ness to take XR-NTX: a) the perceived inability to stop
opioid use for pain, and b) satisfaction with methadone/
buprenorphine were the most frequently cited reasons.
This is the first study, to our knowledge, to assess pa-
tients’ interest in taking a long-acting opioid antagonist
for the treatment of opioid addiction. Rather than
patient-related factors, past studies have examined how
individual and organizational variables can influence
treatment program attitudes towards use of medications
for the treatment of opioid addiction [23]. Fuller et al.
(2005) surveyed outpatient substance abuse treatment
centers and found that standalone substance abuse
clinics were less likely to provide naltrexone [24]. Past
studies have also examined adoption of naltrexone in
the context of alcohol use disorder and found that onlywilling to take XR-NTX by percentage.
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trexone often [25]. In light of the dearth of information
regarding patient profiles that may be appropriate for
XR-NTX, Ling et al. outlined some of the questions re-
garding the role of XR-NTX in opioid dependence, in-
cluding the fact that “no one seems to have figured out
that perhaps we should ask our patients whether they
would like to take [XR-NTX]” [18].
Our findings show a high degree of willingness to
take XR-NTX, particularly among high-intensity heroin
injectors. These results show there is a subset of opioid
users who are willing to try alternatives to traditional
opioid-agonist therapy. This may represent the fact that
methadone has very high penetrance in Vancouver, and
that those who have had a longstanding opportunity to
engage in methadone treatment remain hesitant to take
this medication for programmatic reasons (e.g., daily
witness ingestion) and may be interested in an alterna-
tive [26]. Importantly, Kerr et al. showed in 2005 that
opioid-injecting Aboriginal patients were less than half
as likely to use methadone maintenance than non-
Aboriginal persons [26]. In this regard, it is noteworthy
that the majority of individuals in the non-Caucasian
category in the present study were Aboriginal. While
preliminary, our results suggest that there are likely
reasons for the unwillingness to take opioid-agonist
treatment that are more prevalent among Aboriginal
persons, whereas this population may be more open to
alternatives, including XR-NTX [26]. This is an issue
that will require further study, potentially using qualitative
research methods to explore this question and to examine
willingness and unwillingness to take XR-NTX.
This study has limitations. As our study sample was
generated through street-based recruitment methods, gen-
eralizing our findings to other populations of injection
drug users requires caution. However, it is noteworthy that
the cohort demographics are similar to other local and
international studies of drug users [27-30]. Secondly, as
our outcome of interest was willingness to take XR-NTX,
actual rates of willingness and successful induction onto
XR-NTX will need to be studied in clinical trials in real-
world settings. In particular, all elements of the medica-
tions’ benefits and side-effect profile could not be fully
described in the context of our study. In this regard, as-
sessment of specific populations, including HIV-infected
individuals, is the subject of ongoing investigation, as can
be seen with the National Institute on Drug Abuse
(NIDA) Clinical Trials Network (CTN) 055 CHOICES
study [31]. Finally, socially desirable responding is a con-
cern in studies of marginalized populations [32]. Although
interviewers were trained to build trust and rapport with
participants, and confidentiality was assured, it is possible
we overestimated the percentage of individuals willing to
participate as a result of this concern.In summary, the present study found high rates of
willingness to take XR-NTX in this setting. Interestingly,
daily injection heroin use was independently and posi-
tively associated with willingness to take XR-NTX, while
Caucasian participants were negatively associated with
this choice, suggesting that sub-populations may benefit
from this medication. Although patient-reported expla-
nations for unwillingness were described in this study,
including satisfaction with agonist therapy and concerns
regarding stopping opioid-based pain medications, further
research is needed to investigate real-world acceptability
of XR-NTX as an additional option for the treatment of
opioid use disorder.
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